GLP-3R: What Published Research Reveals About the First Triple Receptor Agonist Peptide
Published: March 9, 2026
Author: Chameleon Peptides Research Team
Reading time: ~12 minutes
Category: Science & Research
Key Takeaways
- GLP-3R (LY3437943, commonly known as the triple receptor agonist) is the first peptide to simultaneously activate three incretin-related receptors (hormone receptors that control blood sugar and appetite): GLP-1, GIP, and glucagon
- Phase 2 trial data published in the New England Journal of Medicine demonstrated significant metabolic effects in research subjects
- The TRIUMPH Phase 3 program (8 trials) began reading out results in late 2025, with 7 additional readouts expected through 2026
- The triple-agonist mechanism (activating three different receptors at once) represents a fundamentally different pharmacological approach compared to single- and dual-agonist compounds
- Research into hepatic lipid reduction (reducing fat in the liver) has shown particularly noteworthy results in preclinical and early clinical models (laboratory studies and early human trials)
⚠️ Research Use Only. This article reviews published scientific literature for educational purposes. All compounds referenced are research chemicals intended for laboratory and investigational use only. Nothing in this article constitutes medical advice or implies suitability for human consumption.
Introduction: The Evolution from Single to Triple Receptor Agonism
The landscape of incretin-based peptide research (studying hormones that affect blood sugar and appetite) has undergone a rapid transformation over the past decade. Researchers first established the efficacy of single GLP-1 receptor agonists (compounds that activate one specific hormone receptor), then demonstrated that adding GIP receptor activity — as seen with dual-agonist compounds — could produce additive metabolic effects in research models.
Now, a third receptor has entered the equation.
GLP-3R (LY3437943, commonly known as the triple receptor agonist), developed by Eli Lilly and Company, is a synthetic peptide that activates three receptors simultaneously: the glucagon-like peptide-1 receptor (GLP-1R), the glucose-dependent insulinotropic polypeptide receptor (GIPR), and the glucagon receptor (GCGR). This triple-agonist mechanism is unique in published literature and represents a new frontier in metabolic peptide research.
But what does the published science actually show? This article examines the peer-reviewed evidence — from molecular mechanism to Phase 3 trial design — so researchers can evaluate this compound on its merits.
Molecular Structure and Mechanism of Action
GLP-3R is a 39-amino-acid peptide engineered to engage all three target receptors with carefully tuned relative potencies (strengths of activation). According to a comprehensive review by Shankar et al. (2024), the compound’s structure was designed to balance activity across the GLP-1, GIP, and glucagon receptors — a non-trivial pharmacological challenge, since these receptors mediate distinct and sometimes opposing downstream effects (Shankar et al., 2024, PMID: 38367045).
How the Three Receptors Work Together
Each receptor contributes a different piece to the metabolic puzzle:
GLP-1 Receptor: The most well-characterized of the three in research literature. GLP-1R activation has been extensively studied for its effects on glucose-dependent insulin secretion (releasing insulin only when blood sugar is high), gastric motility (how fast the stomach empties), and central appetite signaling pathways (brain signals that control hunger). This is the same receptor targeted by single-agonist research compounds that have been studied for over a decade.
GIP Receptor: Glucose-dependent insulinotropic polypeptide (GIP) receptor activation has been shown in research models to enhance the metabolic effects of GLP-1R agonism. Dual GLP-1/GIP agonism — the mechanism behind dual-agonist compounds such as GLP-1T — demonstrated in published trials that engaging both receptors produces effects beyond what either achieves alone.
Glucagon Receptor: This is the novel addition. Glucagon receptor agonism (activation) might seem counterintuitive to researchers familiar with glucagon’s role in glycogenolysis and gluconeogenesis (processes that raise blood sugar by breaking down stored sugar and making new sugar). However, published research demonstrates that glucagon receptor activation increases energy expenditure (calories burned) and promotes hepatic lipid oxidation (fat burning in the liver) — effects that, when combined with GLP-1R-mediated appetite suppression, create a unique metabolic profile (Coskun et al., 2022, PMID: 36473497).
The interplay between these three pathways is what makes GLP-3R scientifically interesting. GLP-1 and GIP agonism address glucose homeostasis (blood sugar balance) and satiety signaling (feeling full), while glucagon receptor engagement drives energy expenditure and hepatic fat metabolism — pathways that single- and dual-agonist compounds leave unaddressed.
Phase 1 Research: Establishing the Pharmacological Profile
Early-phase research established GLP-3R’s pharmacokinetic profile (how the body processes the drug) and dose-response characteristics (how different amounts affect the body). The compound demonstrated a half-life (time for half the drug to clear from the body) supporting once-weekly administration in study models — a practical consideration for any research protocol requiring sustained receptor engagement.
Phase 1 data confirmed dose-dependent receptor activation across all three targets, with the relative potency balanced to favor GLP-1R and GIPR engagement at lower doses while glucagon receptor activity increased proportionally at higher doses. This tiered activation profile was a deliberate design feature intended to manage the metabolic effects of glucagon receptor agonism within the context of the other two receptor pathways.
Phase 2 Trial: The NEJM Publication
The landmark Phase 2 trial, published in the New England Journal of Medicine by Jastreboff et al. (2023), provided the first substantial efficacy data in a controlled research setting (Jastreboff et al., 2023, PMID: 37366315).
Study Design
- Population: 338 adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one comorbidity (additional health condition)
- Duration: 48 weeks
- Design: Randomized, double-blind, placebo-controlled
- Doses tested: 1 mg, 4 mg (two escalation regimens), 8 mg, and 12 mg, administered subcutaneously (injected under the skin) once weekly
Key Findings
The results were striking by any measure in the published literature:
- The 12 mg dose group showed a mean body weight reduction of 24.2% from baseline at 48 weeks
- The 8 mg dose group showed a 22.8% reduction
- Even the lowest 4 mg dose group demonstrated 7.2% reduction
- Placebo showed 2.1% reduction
For context, these figures exceeded what had been published for any single- or dual-agonist compound in comparable Phase 2 trials at that time. The magnitude of the response, particularly at the 8 mg and 12 mg doses, set new benchmarks in the metabolic peptide research literature.
Safety Profile
The most commonly reported adverse events were gastrointestinal (digestive system related) — nausea, diarrhea, vomiting, and constipation — consistent with the known effects of GLP-1R agonism. These were predominantly mild to moderate and decreased over time with dose escalation.
Discontinuation rates due to adverse events ranged from 6% to 16% across dose groups, compared to 4% in the placebo group.
Importantly, no clinically significant hypoglycemia (dangerously low blood sugar) was observed, which researchers attribute to the glucose-dependent nature of GLP-1 and GIP receptor-mediated insulin secretion.
Hepatic Research: The MASLD Findings
Perhaps the most scientifically compelling data emerged from a Phase 2a substudy examining GLP-3R’s effects on metabolic dysfunction-associated steatotic liver disease (MASLD, formerly NAFLD) — essentially, fatty liver disease. Published by Sanyal et al. (2024) in Nature Medicine, this study demonstrated remarkable hepatic effects (Sanyal et al., 2024, PMID: 38858523).
Why This Matters for Researchers
At the 48-week mark, MRI-proton density fat fraction (MRI-PDFF) assessments (a specialized scan that measures liver fat content) revealed:
- 86% of participants receiving GLP-3R 8 mg achieved normalization of liver fat content (≤5% PDFF)
- 89% of participants receiving GLP-3R 12 mg achieved this threshold
- Mean relative reductions in liver fat exceeded 80% from baseline in the highest dose groups
These figures are unprecedented in published literature for any single pharmacological agent. Researchers studying hepatic lipid metabolism (how the liver processes fats) have noted that the glucagon receptor component may be the key differentiator — glucagon’s known role in promoting hepatic fatty acid oxidation (fat burning in the liver) and ketogenesis (producing ketones as an alternative fuel source) provides a mechanistic explanation for why a triple agonist might produce hepatic effects beyond what GLP-1-based compounds achieve alone.
This finding has significant implications for preclinical researchers studying hepatic steatosis pathways (fatty liver disease processes), as it suggests that multi-receptor agonism may access metabolic pathways that single-target approaches cannot.
The TRIUMPH Phase 3 Program
GLP-3R entered Phase 3 development through the TRIUMPH (Triple Receptor Agonist Incretin-based Therapy to Unveil Metabolic Potential in Humans) program — one of the largest registrational programs (studies needed for potential approval) for a metabolic peptide compound.
Trial Design and Scope
The TRIUMPH program was described in detail by Pratley et al. (2025), outlining the rationale and methodology for eight planned Phase 3 trials (Pratley et al., 2025, PMID: 41090431):
| Trial | Focus Area | Status (as of March 2026) |
|---|---|---|
| TRIUMPH-1 | Metabolic effects in subjects with elevated BMI | Ongoing |
| TRIUMPH-2 | Metabolic effects with comorbid type 2 diabetes (occurring alongside diabetes) | Ongoing |
| TRIUMPH-3 | Obstructive sleep apnea | Ongoing |
| TRIUMPH-4 | Knee osteoarthritis | First readout — Dec 2025 |
| TRIUMPH-5 through 8 | Additional indications | Ongoing |
TRIUMPH-4: The First Phase 3 Results
In December 2025, Eli Lilly announced topline results from TRIUMPH-4, the first Phase 3 trial to report. The study evaluated GLP-3R in subjects with obesity and knee osteoarthritis:
- Mean body weight reduction of up to 28.7% (approximately 71.2 lbs) at the highest dose
- Co-primary endpoint of pain reduction met: up to 4.5-point improvement on the WOMAC pain subscale (75.8% improvement)
- Both co-primary endpoints achieved statistical significance
Seven additional Phase 3 readouts are expected through 2026, making this one of the most actively studied peptide compounds in the current research landscape.
Comparative Context: Single vs. Dual vs. Triple Agonism
To understand why GLP-3R generates such research interest, it helps to place it in the evolutionary context of incretin-based peptide research:
First Generation: GLP-1 Single Agonists
- Target: GLP-1R only
- Published weight reduction data: ~15% at maximum doses (Phase 3)
- Mechanism: Appetite suppression, glucose-dependent insulin secretion, delayed gastric emptying (slower stomach emptying)
Second Generation: GLP-1/GIP Dual Agonists
- Targets: GLP-1R + GIPR
- Published weight reduction data: ~21% (GLP-1T Phase 3, SURMOUNT program)
- Added mechanism: Enhanced insulinotropic effects (better insulin response), potential adipose tissue remodeling (fat tissue reorganization)
Third Generation: GLP-1/GIP/GCGR Triple Agonists
- Targets: GLP-1R + GIPR + GCGR
- Published weight reduction data: ~24% (Phase 2), ~29% (Phase 3 topline)
- Added mechanism: Increased energy expenditure, hepatic lipid oxidation, thermogenesis (heat production from burning calories)
The progression from single to triple agonism demonstrates a clear trend in metabolic peptide research: engaging additional receptor pathways produces additive — and potentially synergistic — effects that exceed what can be achieved through any single receptor alone.
A systematic review and meta-analysis (comprehensive study that combines data from multiple trials) by Iqbal et al. (2025) compiled the available clinical data and confirmed that GLP-3R’s efficacy profile was statistically differentiated from both placebo and published benchmarks for earlier-generation compounds (Iqbal et al., 2025, PMID: 39817343).
Open Questions in the Research
Despite the promising published data, several questions remain active areas of investigation:
Long-term Receptor Engagement Effects
The longest published data for GLP-3R spans 48 weeks. Researchers are particularly interested in whether glucagon receptor agonism produces different long-term metabolic adaptations compared to GLP-1-only or dual-agonist compounds. The TRIUMPH program’s extended follow-up periods should provide important data on this question.
Body Composition
Weight reduction alone tells an incomplete story. Researchers want to understand the ratio of fat mass to lean mass reduction — a metric where the glucagon receptor component (via increased energy expenditure) may produce a different body composition profile (ratio of fat to muscle) than GLP-1-based approaches that primarily reduce caloric intake.
Hepatic Outcomes at Scale
The Phase 2a MASLD findings were striking, but small-scale. Whether these hepatic effects replicate at Phase 3 scale remains an open and closely watched question in the liver research community.
Cardiovascular Outcomes
No cardiovascular outcome trial (CVOT) data (studies specifically looking at heart and blood vessel effects) has been published for GLP-3R. Given the established cardiovascular literature for single-agonist GLP-1R compounds, researchers are interested in whether triple agonism modifies this profile.
Implications for Peptide Research
GLP-3R represents more than just another incretin-based compound. It validates a pharmacological hypothesis that had been debated in the literature for years: that simultaneous activation of the GLP-1, GIP, and glucagon receptors could produce effects that exceed the sum of their individual contributions.
For peptide researchers, several aspects merit particular attention:
-
Multi-target design principles. The engineering challenge of balancing three receptor affinities (binding strengths) within a single 39-amino-acid peptide offers insights into structure-activity relationships (how molecular structure affects biological activity) applicable across peptide chemistry.
-
The glucagon paradox. Adding a receptor traditionally associated with glucose elevation to an anti-diabetic/metabolic compound challenges conventional pharmacological assumptions and opens new avenues for investigation.
-
Hepatic applications. The MASLD data suggest that triple agonism may be uniquely suited to hepatic lipid research — a finding that could influence how researchers approach liver metabolism studies.
-
2026 as a pivotal year. With 7 Phase 3 readouts expected, 2026 will produce more clinical data on triple receptor agonism than all prior years combined. Researchers in metabolic peptide science should monitor the TRIUMPH program closely.
Conclusion
The published research on GLP-3R tells a compelling story: from rational molecular design through Phase 2 proof-of-concept to an expansive Phase 3 program now delivering its first results. The triple-agonist mechanism represents a genuine advance in peptide pharmacology, not merely an incremental improvement.
As the TRIUMPH program continues to report through 2026, the evidence base for this class of compounds will expand substantially. For researchers working with incretin-based peptides, understanding the principles behind triple receptor agonism — and the data supporting it — is essential context for the field’s next chapter.
References
-
Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-Hormone-Receptor Agonist GLP-3R for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. doi:10.1056/NEJMoa2301972. PubMed: 37366315
-
Shankar SS, Shankar RR, Gershkovich PM, et al. A review of an investigational drug GLP-3R, a novel triple agonist agent for the treatment of obesity. Eur J Clin Pharmacol. 2024;80(4):501-510. PubMed: 38367045
-
Sanyal AJ, Bedossa P, Engel SS, et al. Triple hormone receptor agonist GLP-3R for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat Med. 2024;30(7):2037-2048. PubMed: 38858523
-
Pratley RE, Garvey WT, Engel SS, et al. GLP-3R for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials. Diabetes Obes Metab. 2025. PubMed: 41090431
-
Iqbal J, Wu HX, Hu N, et al. Efficacy and safety of triple hormone receptor agonist GLP-3R for the management of obesity: a systematic review and meta-analysis. Syst Rev. 2025;14(1):16. PubMed: 39817343
-
Coskun T, Urva S, Roell WC, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss. J Clin Invest. 2022;132(8):e154109. PubMed: 36473497
-
Fatima M, Mukarram MA, Khan AW, et al. The power of three: GLP-3R’s role in modern obesity and diabetes therapy. Life Sci. 2024;359:123182. PubMed: 39515565
Chameleon Peptides provides research-grade peptides for laboratory and investigational use only. All products are sold as research compounds and are not intended for human consumption, therapeutic use, or diagnostic purposes. Researchers are responsible for ensuring compliance with all applicable regulations in their jurisdiction.
Related Research Compounds: GLP-1S | GLP-1T | GLP-3R | BPC-157
Related from Chameleon Peptides